Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intracavitary chemotherapy.

M Markman

    Critical Reviews in Oncology/Hematology
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Intracavitary chemotherapy offers greater drug exposure in body cavities compared to plasma. Clinical trials show promise for ovarian carcinoma and mesothelioma, but further research is needed to optimize treatment and confirm survival benefits.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Differences in Discounting Behavior and Brain Responses for Food and Money Reward.

    eNeuro·2024
    Same author

    Apical hypertrophic cardiomyopathy: A case series at a Brazilian referral center with a maximal follow-up of 15 years.

    Annales de cardiologie et d'angeiologie·2021
    Same author

    Platinum-Gemcitabine-Avastin (PGA) for platinum-resistant/refractory ovarian cancer.

    European journal of gynaecological oncology·2018
    Same author

    Intravenous vitamin C in the supportive care of cancer patients: a review and rational approach.

    Current oncology (Toronto, Ont.)·2018
    Same author

    Surgical intervention in relapsed ovarian cancer is beneficial: contra.

    Annals of oncology : official journal of the European Society for Medical Oncology·2013
    Same author

    The use of bevacizumab in the management of ovarian cancer: an argument for single-agent rather than combination therapy.

    Annals of oncology : official journal of the European Society for Medical Oncology·2011
    Same journal

    Estrobolome and the Endocrine-Microbiome Axis in Breast and Endometrial Carcinogenesis.

    Critical reviews in oncology/hematology·2026
    Same journal

    Remodeling the Immune Microenvironment: Engineering IL-2 Variants to Overcome Clinical Bottlenecks in PD-1 Inhibitor plus Chemotherapy.

    Critical reviews in oncology/hematology·2026
    Same journal

    Neoadjuvant Immunotherapy in Melanoma: From Pathologic Response to Response-Adapted Management.

    Critical reviews in oncology/hematology·2026
    Same journal

    DNA polymerase epsilon catalytic subunit (POLE) in cancer: Implications for tumor biology and therapeutic strategies - A comprehensive review.

    Critical reviews in oncology/hematology·2026
    Same journal

    Long non-coding RNAs in triple-negative breast cancer: emerging drivers of tumor biology, prognosis, and drug resistance.

    Critical reviews in oncology/hematology·2026
    Same journal

    Alternative splicing in breast cancer drug resistance: Mechanisms, therapeutic targeting, and clinical translation.

    Critical reviews in oncology/hematology·2026
    See all related articles

    Area of Science:

    • Oncology
    • Pharmacology
    • Clinical Medicine

    Background:

    • Intracavitary drug administration can achieve higher drug concentrations within body cavities than in plasma.
    • This approach is being investigated for malignancies that primarily reside within body cavities, such as ovarian carcinoma and malignant mesothelioma.
    • Previous studies have established the safety and efficacy of various agents administered individually or in combination via intracavitary delivery.

    Purpose of the Study:

    • To evaluate the potential of intracavitary chemotherapy for treating malignancies confined to body cavities.
    • To review existing clinical evidence supporting the use of intracavitary chemotherapy for ovarian carcinoma and malignant mesothelioma.
    • To identify areas for future research, including optimal drug selection, dosage, scheduling, and comparison with systemic chemotherapy.

    Related Experiment Videos

    Main Methods:

    • Review of pharmacokinetic modeling and clinical investigations.
    • Analysis of early clinical trial data for intracavitary chemotherapy in relevant malignancies.
    • Discussion of the rationale for intracavitary treatment based on tumor behavior.

    Main Results:

    • Pharmacokinetic data and clinical studies confirm superior drug exposure in the target cavity versus plasma.
    • Early clinical trials demonstrate significant therapeutic activity of intracavitary chemotherapy for ovarian carcinoma and malignant mesothelioma.
    • Safety and efficacy of individual and combination agents have been established.

    Conclusions:

    • Intracavitary chemotherapy is a rational and promising treatment strategy for body cavity malignancies.
    • Further controlled clinical trials are necessary to define optimal treatment regimens and to ascertain if combination intracavitary chemotherapy improves patient survival compared to standard systemic therapy.